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Abstract
Background Although severe asthma can be life-threatening, many patients are unaware they have this condition.
Objectives Patient Understanding Leading to Assessment for a Severe Asthma Referral (PULSAR) is a novel, multidiscipli-
nary working group aiming to develop and disseminate a global, patient-centered description of severe asthma to improve 
patient understanding of severe asthma and effect a change in patient behavior whereby patients are encouraged to visit their 
healthcare professional, when appropriate.
Methods Current definitions from patient organization websites, asthma guidelines, and medication information for key 
asthma drugs were assessed and informed a multidisciplinary working group, convened to identify common concepts and 
terminology used to define severe asthma. A patient-centered description of severe asthma and patient checklist were drafted 
based on working-group discussions and reviewed by an external behavioral scientist for patient understanding and relevance. 
These were tested using an online US/Canadian survey.
Results The patient-centered description of severe asthma and patient checklist were reviewed and re-drafted by the authors. 
The text was simplified following the behavioral-scientist review. The survey (n = 153) included 105 patients with severe 
asthma. Of those with severe asthma, 92.2% of patients reported that the description was consistent with their experiences 
of severe asthma and 92.6% of patients reported that the PULSAR initiative would encourage them to visit their healthcare 
provider.
Conclusion A patient-centered description of severe asthma has been developed and tested using patients with severe asthma; 
this description will allow patients to assess whether they might have severe asthma and prompt them to visit their healthcare 
provider, if appropriate.
Plain Language Summary
Severe asthma is a serious form of asthma. It can be harmful to your health and affect the way you live your life. Some patients 
do not know that they have severe asthma or visit their doctor and ask for help. A new group, called Patient Understand-
ing Leading to Assessment for a Severe Asthma Referral (PULSAR), would like to help patients understand their asthma 
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symptoms. They have developed a description of severe asthma and a checklist. These may help patients decide if their 
symptoms require a visit to the doctor.
The PULSAR description and checklist were developed in four parts. Part 1 looked at if patients and doctors/nurses defined 
severe asthma in the same way. Results showed that patients defined severe asthma using symptoms and doctors defined 
severe asthma using treatments. In Part 2, patients, patient advocacy group members, nurses, doctors, specialists, and a sci-
entist talked about the ways severe asthma were described in Part 1. The group agreed on a set of words to describe severe 
asthma. These words were then used in the PULSAR description and checklist. In Part 3, a behavioral scientist reviewed the 
PULSAR description and checklist. They said that simple language would make it easy to understand. In Part 4, patients 
with severe asthma were asked what they thought about the description and checklist using an online survey. The survey 
showed that almost all patients understood the description and checklist. Many patients said that the description and checklist 
encouraged them to see a doctor.
A new description of severe asthma and checklist have been developed by PULSAR. Testing shows that they should encour-
age patients to visit their doctor when needed. This may help patients understand their symptoms and help doctors make the 
correct diagnosis. This should help patients get the support and treatment they need.
Key Points for Decision Makers 
The new Patient Understanding Leading to Assessment 
for a Severe Asthma Referral (PULSAR) description of 
severe asthma could improve patient understanding of 
the condition and allow patients to assess whether their 
asthma may be severe.
The PULSAR description should encourage patients to 
visit their primary care physician, who may refer them 
for specialist investigations, if appropriate.
1 Introduction
Severe asthma is a life-threatening and debilitating condition 
that is associated with significant disease burden that can 
affect health-related quality of life (HRQoL) [1–3]. How-
ever, many patients with severe asthma are often unaware 
that their asthma is severe, possibly due to the different 
definitions provided by patient websites [4–17] or because 
many patients often underestimate their condition, believ-
ing that their symptoms are acceptable [18]. Consequently, 
some patients do not visit their primary care provider (PCP) 
and do not receive the appropriate level of care [18]. In addi-
tion, healthcare professionals (HCPs), who are faced with 
multiple asthma guidelines that differ in their approach to 
defining severe asthma [2, 3, 19–25], may not use language 
that patients understand. This may complicate the diagno-
sis and management of the disease and potentially impact 
on the number of patients referred to specialists and their 
subsequent access to appropriate therapies [26]. Therefore, 
there is a need to improve patient understanding of severe 
asthma and effect a change in patient behavior whereby 
patients are appropriately encouraged and have more confi-
dence to visit and discuss their disease with their PCP; the 
PCP may then make a referral to a specialist [3]. Patient 
Understanding Leading to Assessment for a Severe Asthma 
Referral (PULSAR) is a new multidisciplinary initiative that 
aims to develop and disseminate a global patient-centered 
description of severe asthma for use by patients. This PUL-
SAR description will allow patients to assess whether they 
might have severe asthma and prompt them to visit their 
PCP, if appropriate. This article describes the development 
of the PULSAR description. This was based on four dis-
tinct phases, which involved an assessment of current severe 
asthma definitions (Part 1); a discussion on key concepts and 
terminology in severe asthma by a multidisciplinary work-
ing group (Part 2); an evaluation by an external behavioral 
scientist (Part 3); and, finally, a patient survey to sense check 
the description (Part 4).
2  Part 1: Assessment of Current Severe 
Asthma Definitions
To identify the current definitions and terminology available 
to both English-speaking patients and HCPs, patient organi-
zation websites, current global and regional asthma guide-
lines including regulatory body websites, and medication 
information for key asthma drugs were searched and ana-
lyzed in April 2018. Further details are summarized in Addi-
tional File 1 of the electronic supplementary material. Over-
all, patient advocacy group websites defined severe asthma 
using symptoms [8, 12–15], possibly due to their ease of 
understanding and relevance to patients. Specific phrases 
used included ‘difficulty breathing’ [8], ‘uncontrolled’ [12], 
‘worsening of symptoms’ [13], ‘life-threatening’ [8], ‘symp-
toms during the day’ [14], ‘night-time awakenings every 
night’ [14], or ‘symptoms that do not improve or remain 
despite usual/preventer medications’ [12, 15]. Additional 
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phrases used by patient websites to define severe asthma 
included ‘inability to take part in activities’ [8], ‘quality of 
life’ [9], and ‘level of medical care’ [8]. The Severe Asthma 
Foundation and Asthma Canada websites defined severe 
asthma using a treatment-based approach, based on high-
dose treatment and a number of additional controllers [8, 
16]. Only Asthma UK mentioned that severe asthma can 
only be diagnosed once poor adherence, inadequate tech-
nique, and other causes and triggers for symptoms have been 
ruled out [12]. Interestingly, several of the patient group 
websites did not include a definition of severe asthma [4–7, 
10, 11, 27].
In contrast, most asthma guidelines base their definitions 
on treatment failure according to clinical criteria, despite 
receiving high-intensity treatment (medium- or high-dose 
controller medications) [2, 3, 19, 20, 22–25] or when 
high-dose treatment is reduced [3]. The sudden worsen-
ing of symptoms (asthma attacks/flare-ups/exacerbations) 
is considered by the Global Initiative for Asthma (GINA), 
the National Institutes of Health (NIH), and the Austral-
ian, Japanese, and World Health Organization (WHO) 
guidelines as part of their definition of severe asthma [2, 
20, 23, 25], while other guidelines refer to these events as 
an acute episode that is separate to disease severity [21]. 
Other components considered in the guidelines include lung 
function [2, 21–23, 25], level of medical care [19], clinical 
investigations (e.g., eosinophil counts, allergy testing) [2, 3, 
20–22], asthma phenotypes [2, 3, 19–22], and patient history 
of near fatal asthma or inpatient admissions [21]. Although 
some guidelines do not differentiate between severe and 
difficult-to-control or uncontrolled asthma [19, 25], many 
have specified that asthma is not considered severe if it can 
be controlled following correction/treatment of poor adher-
ence, inappropriate or incorrect use of medications, environ-
mental triggers, and comorbidities [2, 3, 21, 22, 24]. Of note, 
the WHO and NIH guidelines include a definition of severe 
asthma for untreated populations [20, 25]. These definitions 
have been specified to either consider patient populations in 
developing countries, who do not have access to treatments 
such as inhaled corticosteroids (ICS) [20], or patients at first 
presentation [25]; however, these patients might be consid-
ered by some guidelines as having mild–moderate asthma 
if symptoms improve upon treatment [20]. It is important to 
note that there has been a shift in the medical definition of 
severe asthma over time. In the past, definitions varied mark-
edly, often with separate definitions for patients before and 
during treatment. However, since the European Respiratory 
Society/American Thoracic Society (ERS/ATS) Task Force 
was established in 2009, with the resulting publication of the 
ERS/ATS Guidelines on Severe Asthma in 2014 [22], there 
has been general agreement that severe asthma is asthma that 
remains uncontrolled (in terms of symptoms, lung function, 
and/or exacerbations) despite high-dose treatment or that 
worsens when treatment is stepped down.
Overall, the labeling information (e.g., Prescribing Infor-
mation, Summary of Product Characteristics, etc.) provided 
for severe asthma drugs does not specifically define severe 
asthma. However, the labeling information for the ICS/long-
acting-β2-agonist (LABA) class indicates that these drugs 
can be given to patients not adequately controlled on ICS 
or whose treatment requires ICS/LABA [28], consistent 
with the treatment-based approach described by the asthma 
guidelines. Likewise, the injectable biologics are indicated 
for patients inadequately controlled on high-dose inhalers 
plus an additional controller medication [29–32], although 
they differ in that they are only indicated for specific forms 
of asthma (e.g., eosinophilic and allergic asthma) [29–32]. 
Therefore, the labeling information does not make it clear 
these drugs are indicated for severe asthma.
3  Part 2: Identification of Key Terminology 
and Concepts for the PULSAR Description
A multidisciplinary working group convened in June 2018 
to discuss the current asthma definitions and produce a draft 
patient-centered description of severe asthma. This group 
included two patients with severe asthma, four patient advo-
cacy group members, two nursing specialists, one PCP, three 
respiratory specialists, and one clinical scientist from GSK. 
Attendees were from a variety of countries, including Aus-
tralia, Belgium, Canada, France, United Kingdom (UK), 
and United States of America (USA). During the working 
group, attendees reviewed the concepts and terminology 
used by the patient advocacy group websites, asthma guide-
lines, and medication information guidelines and, agreed on 
common concepts (treatments, symptoms, activity levels, 
and emotions) used to describe severe asthma. Attendees 
also voted on preferred, patient-friendly terms for inclusion/
exclusion in the description. A patient-centered description 
of severe asthma was drafted based on these discussions, 
which underwent subsequent reviews and re-drafting by the 
authors (detailed below).
3.1  Concepts
3.1.1  Symptoms
The most significant severe symptoms of asthma described 
by the patients included the inability to walk up a flight 
of stairs, persistent wheezing, the proverbial ‘elephant on 
your chest’, and recurrent chest infections. Patients noted 
that these symptoms can occur daily and never go away. 
As patients with milder forms of asthma may also experi-
ence these symptoms (especially during an asthma attack/
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flare-up), the working group decided these symptoms could 
not be used to differentiate between severe and milder forms 
of asthma. Instead, to ensure that the concept was specific 
to severe asthma, symptoms were included if they were 
severe and frequently worsened (asthma attacks/flare-up), 
or required treatment with steroid tablets, use of emergency 
services, or hospitalization.
3.1.2  Activities
The patients in the working group expressed that they expe-
rience persistently reduced activity levels, meaning that they 
cannot do the things they want to do or require support from 
others to help them with everyday activities. Their reduced 
activity levels were related to their severe asthma symptoms, 
which affect their ability to maintain a conversation or activ-
ity, attendance at work, capacity to apply for their preferred 
job, exercise (patients cannot exercise as they would like or 
as much as their peers), and intimacy. As patients empha-
sized that they had to make financial, social, and lifestyle 
compromises to accommodate their asthma symptoms, more 
so than in milder forms of asthma, the PULSAR description 
included the compromises that patients with severe asthma 
are often forced to make.
3.1.3  Emotions
The patients discussed how living with severe asthma 
affected their lives in terms of their feelings. Common expe-
riences included fear, frustration, fatigue, depression, help-
lessness and embarrassment, and that nothing seems to work 
in terms of treatment. The patients and patient advocacy 
group members recommended that the PULSAR description 
should encompass patient emotions as this concept is rarely 
covered by other definitions. However, as some of these 
emotions are experienced by patients with milder forms of 
asthma, the PULSAR description was drafted to encompass 
the overall impact of these emotions on patients’ lives by 
stating that severe asthma can affect a patient’s entire life. 
This is likely to be specific to severe asthma.
3.1.4  Treatment
The working group discussed the different treatment options 
for asthma and how they relate to severity, specifically con-
troller and reliever medications as well as oral corticosteroid 
(OCS) use. The HCPs felt that patients with severe asthma 
often have symptoms despite receiving multiple moder-
ate-/high-dose controller medications or if they reduce 
high-intensity treatment. However, the patients and patient 
advocacy group members were not sure whether this con-
cept was patient-friendly and felt that it was possibly more 
relevant to HCPs. To ensure that the PULSAR description 
was specific to severe asthma, the working group decided 
that the PULSAR description should state that patients with 
severe asthma experience symptoms despite taking multi-
ple high-dose medications as agreed. Reliever medications 
were mostly relevant to the patients as they noticed that they 
require them frequently (more than twice per week as recom-
mended by GINA 2018 [2]), either in the form of inhalers or 
nebulizers, to gain relief from symptoms. However, as HCPs 
felt that the use of relievers is relevant to both patient groups 
with uncontrolled and/or severe asthma, reliever use could 
not be used to differentiate between these two patient groups. 
Therefore, this concept was not included in the PULSAR 
description to avoid confusion. As both patients mentioned 
that they often (≥ 2 times a year) require courses of steroid 
tablets when they experience asthma attacks/flare-ups, the 
use of steroid tablets was included. Although the patients 
also described the unwanted side effects associated with 
OCS (e.g., weight gain, irritability, changes in mood, moon 
face, insomnia), which can discourage patients from tak-
ing their medications as prescribed, this concept was not 
included in the PULSAR description as it could be relevant 
to patients with milder forms of asthma.
3.1.5  Call‑to‑Action
The patient advocacy group attendees suggested including a 
‘call-to-action’ within the PULSAR description to provide 
patients with advice on when to visit their PCP and what 
to expect in terms of secondary care activities. However, 
there was a difference between the HCPs and patients/patient 
advocacy group members on the language used to describe 
referrals. For example, patients and patient advocacy group 
members suggested that if patients think that they might 
have severe asthma they should visit their PCP and ask to 
be referred to a specialist. However, HCPs suggested that 
advising patients to ask for a referral may be too strong. To 
accommodate the views of both the patients/patient advo-
cacy group members and HCPs, the PULSAR description 
recommended that patients should visit their PCP and dis-
cuss the possibility of a referral to a specialist.
3.2  Terminology
Terms were considered suitable for inclusion in the PULSAR 
description if they were patient-friendly and relevant for severe 
asthma. Terms were excluded if they could be interpreted dif-
ferently by patients and HCPs or if they implied blame to 
either party, as this may lead to patients feeling guilty and 
not seeking help (Table 1). In instances where terms were 
appropriate for severe asthma but were not specifically patient-
friendly, the group discussed alternative phrasing so that they 
could be included in the PULSAR description. For exam-
ple, many attendees thought that ‘exacerbations’ was often 
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misunderstood by patients and decided that ‘asthma-flares’ 
or ‘flare-ups’ (North American terms) or ‘asthma attacks’ 
(UK term) would be easier to understand by patients. Simi-
larly, many thought that the term ‘oral corticosteroids’ may 
be difficult to interpret by patients, so ‘steroid tablets’ was 
suggested as an alternative. When discussing if patients have 
taken their medications as prescribed, it was suggested that 
patients may feel blamed for not following their PCP’s advice. 
Therefore, the patients requested that the phrase ‘as agreed’ 
be included as an alternative to ‘as prescribed’ to remove any 
inference of blame and to demonstrate that it was a mutual 
agreement between the patient and PCP. Other aspects of the 
PULSAR description discussed by the group were whether 
to define uncontrolled asthma and whether to use the term 
‘life-threatening’. The group decided not to describe the differ-
ences between severe and uncontrolled asthma in the PULSAR 
description to avoid confusion for the patient, as ultimately the 
description was designed to get the patient to the doctor. The 
term ‘life-threatening’ was kept as requested by the patients, 
as it encompasses the magnitude of the condition from the 
patient’s perspective. To allow for the PULSAR description 
to be relevant globally, US- and UK-friendly terms were used; 
general practitioner (GP; UK term) and PCP (North Ameri-
can term) were both used, and emergency services was used 
instead of Emergency Room (North American term) and Acci-
dent and Emergency (UK term).
3.3  Patient Materials
Two different patient materials were proposed to accompany 
the PULSAR description and assist patients with assessing 
whether they should visit their PCP for their condition. 
However, the authors decided to focus on one of the patient 
materials, a patient checklist, as a checkbox system provided 
an easy means for patients to assess their condition. The 
checklist delineates characteristics of severe asthma into red 
and yellow characteristics, where red characteristics indicate 
clear signals of severe asthma and yellow describe charac-
teristics that are both concerning and suggestive of severe 
asthma. Initially, ‘red flags’ and ‘risk factors’ were consid-
ered instead of red and yellow characteristics, but these were 
deemed to be confusing for patients. All characteristics were 
included based on the working group discussions described 
above.
4  Part 3: Behavioral Scientist
The revised PULSAR description and checklist were 
reviewed by an external behavioral scientist and certified 
asthma educator to gain feedback on whether they would 
be understandable by patients and if they could effect a 
change in patient behavior. The review identified that both 
the PULSAR description and checklist were appropriate for 
patients with severe asthma but that they could be simplified 
to improve their accessibility to patients with a low reading 
and health literacy age. It was also recommended that the 
language should be more compelling, forthright, persuasive, 
personal, and globally relevant.
Upon recommendation by the behavioral scientist, the 
checklist was simplified to a shopping-list design and the 
items included on the list were referred to as ‘signs’. These 
signs were listed as either ‘clear signs of severe asthma’ 
(red) or ‘concerning signs of severe asthma’ (yellow). The 
language was simplified to a reading level of around 14 years 
old (Flesch–Kincaid Grade Level 8), written in the first per-
son and modified so that it would motivate patients to visit 
their PCP.
5  Part 4: Survey
The final PULSAR description was reviewed by adult 
patients who self-reported as having severe asthma through 
the Allergy Asthma Network (Fig. 1). Further details of 
Table 1  Terminology to be excluded from the patient-centered 
description
a Taken from Pavord et  al. [43] regarding patient behavior and envi-
ronment. Aspects include unscheduled visits, failure to attend 
appointments, poor adherence, smoking, allergenic environment, 
denial, depression, and disorganization
Category Terms
Disease descriptor Uncontrolled
Phenotype
Reversibility
Chronic
Acute severe
Lack of control
A state of permanency
Treatment-resistant
Refractory
Impacts Shakes
Exacerbations Inpatient/outpatient visits
Treatments Monoclonal antibodies
Bronchodilator
Biologics
Injections
Bronchial thermoplasty
Leukotriene receptor 
antagonists
Oral
Color of inhaler (e.g., 
brown or blue inhalers)
Confounders Non-adherence
Confounders
Compliance
Diligence
Harmfula
Clinical investigations Spirometry
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the survey process are included in Additional File 1 of 
the electronic supplementary material. Of the 153 patients 
who initiated the survey, 75.2% were female and 62.1% 
were 35–64 years of age versus 25–35 years (16.3%), 
over 65 years (12.4%) or 18–24 years of age (9.2%). Most 
(92/152; 60.5%) patients reported having asthma for 15+ 
years, while others reported having asthma for 0–2 years 
(17/152; 11.2%), 3–5 years (8/152; 5.3%), and 6–15 years 
(35/152; 20.0%). Of those who had been told by their doc-
tor that they had severe asthma (105/153; 68.6%), 101/104 
(96.2%) patients reported that they understood the PUL-
SAR description and 95/103 (92.2%) patients reported that 
the description was consistent with their own experiences 
of severe asthma. Consistent with the description, 63/105 
(60.0%) patients felt that their experience of asthma was 
potentially life-threatening and 86/104 (82.7%) felt like 
asthma forced them to make unwanted changes to their 
daily lives. The terminology used within the description, 
including ‘multiple high-dose inhalers’, ‘steroid tablets’ 
and ‘asthma attacks/flare-ups’ were reported as being 
understood by 96.2–98.1% of patients. Interestingly, 
slightly more (64.8%) patients preferred the term ‘flare-
ups’ versus ‘asthma attacks’, which may be due to the sur-
vey being conducted in the US where the term ‘flare-ups’ 
is commonly used. A total of 100/105 (95.2%) patients 
reported that they understood the PULSAR checklist and 
of those who did not, one patient reported it was too long 
and one reported it was difficult to complete. The remain-
ing patients did not provide a reason. Overall, as most 
(n = 87/94; 92.6%) patients reported that the PULSAR 
description and checklist would encourage them to see 
their PCP about their asthma, no further changes were 
made to the terminology or concepts included in either.
100
Percentage of patients (%)
0 10 20 30 40 50 60 70 80 90
Do you understand the PULSAR description of severe asthma?
n=105
Do you feel that your asthma is dangerous and 
potentially life threatening?
n=105
Does your asthma force you to make 
unwanted changes to your daily life?*
n=104
Do you understand the meaning of “multiple high-dose inhalers”
n=105
Do you understand what “steroid tablets” are?
n=105
Do you understand the terms “flare-ups” or “asthma attacks”?†
n=105
Is the PULSAR checklist easy to understand and use?
n=105
Is there anything that you would change or add to the 
PULSAR description or checklist?
n=98
Would the PULSAR description and/or checklist encourage
you to see your PCP who might refer you to a specialist?
n=94
Is the PULSAR description of severe asthma consistent 
with your own experiences of severe asthma?
n=103
YesNoSometimes
Fig. 1  The results of the patient survey. *Examples for unwanted 
changes to daily life provided in the survey include ‘are you unable to 
do your normal day-today activities like household chores, meet with 
friends, work opportunities?’ †68/105 (64.7%) patients preferred the 
term ‘flare-ups’
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6  Discussion
As asthma is associated with debilitating symptoms that can 
affect HRQoL [1–3, 33], patients with severe asthma may 
benefit from a referral to a specialist to identify the most 
appropriate treatment options [26]. However, if patients 
are unaware that they have severe asthma they do not visit 
their PCP and receive the appropriate level of care. There-
fore, a novel patient-centered description and accompany-
ing checklist were developed to help patients understand 
and assess whether they might have severe asthma with the 
aim of encouraging patients to visit their PCP, who may 
refer them to a specialist, if appropriate. The final PULSAR 
description and patient checklist are included in Figs. 2 and 
3, respectively. According to the feedback received from 
a behavioral scientist and patients with severe asthma, the 
PULSAR description and checklist are considered to be rel-
evant to this patient group and are likely to effect a change 
in patient behavior. The patient survey also demonstrated 
The PULSAR description of severe asthma
Severe asthma is a life-threatening condition. It can affect 
your entire life by forcing you to make unwanted changes 
to your daily activities. If you have severe asthma, you will 
experience frequent and severe worsening of asthma 
symptoms (asthma attacks/flare-ups). This will happen 
despite you taking multiple high-dose inhalers. These 
attacks or flare-ups often occur more than once per year. 
They will require steroid tablets or use of emergency 
services or hospitalization. 
What next?
If you think you might have severe asthma, you should see 
your doctor. They may refer you to a specialist. A specialist 
may run some tests to see if you have severe asthma. If you 
have severe asthma, your doctor or specialist may be able 
to help you reduce your symptoms and improve your life.
Fig. 2  The final Patient Understanding Leading to Assessment for a 
Severe Asthma Referral (PULSAR) description of severe asthma
Fig. 3  The Patient Understand-
ing Leading to Assessment 
for a Severe Asthma Referral 
(PULSAR) checklist for patients 
to assess whether they might 
have severe asthma
Do you have severe asthma?
Please consider the Clear (Red) and Concerning (Yellow) signs of severe asthma in the 
checklist below. Please put a “X” in the box next to any of the signs that apply to you. 
If any of the Clear (Red) signs apply to you or if you have put an “X” next to some of the 
Concerning (Yellow) signs and you are worried, please visit your doctor and share this 
information. The goal is to help you reduce your symptoms and improve your quality of life.
Severe asthma checklist:
sngis gninrecnoCsngis raelC
□ I regularly visit the emergency 
services or have stayed in hospital
□ I cannot do the things that I want to 
do, like exercise or household chores
□ I am often absent from work or school
due to asthma
□ I often need help from someone 
to conduct my daily activities, like 
cooking or laundry 
□ I often feel that nothing works to help 
with my symptoms
□ Asthma puts a stress on 
my relationships
□ I often feel that asthma is controlling 
my life
□ I am often forced to make unwanted 
changes to my daily life
□ I am scared of dying from asthma □ I often feel depressed or anxious due 
to asthma
□ My disease is unpredictable with 
regular asthma attacks (flare-ups)
□ I often feel isolated and alone
□ I have symptoms that never go away □ I often feel like I have a heavy weight 
pushing down on my chest
□ I have had two or more sets of steroid 
tablets in 12 months
□ My coughing often interferes with my
normal activities
□ I use my reliever/rescue medication 
more than twice a week even 
though I take my controller 
inhaler(s) and tablets 
□ My symptoms often keep me awake 
at night
□ I cannot walk upstairs without 
becoming short of breath
□ I regularly use nebulizers to relieve 
my symptoms
□ I forget to take my controller inhalers
□ I am afraid of the side effects of my
asthma medications
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that no further changes to the PULSAR description and 
checklist were required and both items fulfilled the PUL-
SAR initiative.
The definition of severe asthma published in the 2019 
GINA pocket guide for difficult-to-treat and severe asthma 
describes severe asthma as “asthma that is uncontrolled 
despite adherence with maximal optimized therapy (GINA 
Step 4 or 5) and treatment of contributory factors (such as 
inhaler technique), or that worsens when high-dose treat-
ment is decreased” [3]. The GINA pocket guide also sug-
gests that the severe asthma phenotype should be assessed 
for patients uncontrolled on high-dose ICS or maintenance 
OCS within a specialist clinic [3]. These assessments include 
tests for various biomarkers of type 2 airway inflammation, 
including blood eosinophil counts ≥ 150 cells/µL, sputum 
eosinophil counts ≥ 2%, and/or fractional exhaled nitric 
oxide (FeNO) ≥ 20 ppb, as well as determining whether their 
asthma is allergy driven. This definition of severe asthma in 
GINA is in agreement with the definition from the Interna-
tional (ERS/ATS) Guidelines on Severe Asthma that have 
been almost universally accepted by the respiratory com-
munity [22]. Although the PULSAR description of severe 
asthma is largely consistent with this medical definition, it 
is simpler in its language to aid understanding and broader 
in its scope, including patient-centered concepts to capture 
their experience of this disease and to provide prompts to 
the patient to visit their doctor. Indeed, establishing a defini-
tion of severe asthma that patients can understand and use 
is of importance as various national initiatives worldwide 
allow patients to take more ownership in their own care. 
For example, in the US, since this working group was con-
vened, patients now have access to their electronic medical 
records. Additionally, guidance from the National Institute 
for Health and Care Excellence (NICE) in the UK for the 
use of objective testing to confirm a diagnosis may drive 
more referrals [34].
There have been many studies that support the findings 
of the working group and the concepts and items chosen by 
the working group for inclusion in the PULSAR description 
and checklist, respectively. Previous studies have demon-
strated that severe asthma can affect a patient’s entire life, 
forcing them to make lifestyle compromises, consistent with 
the findings of the working group [35–39]. The European 
Fighting for Breath survey of severe asthma estimated that 
more than 6 million people live in fear that their next attack 
will be fatal and many restrict their physical activities or 
do not participate in social activities [38]. Supporting this, 
another study from the UK found that most (22/25) patients 
with severe asthma do not meet the NICE recommended 
levels of physical activity, mostly due to symptoms [36]. 
Furthermore, according to an Australian interview study and 
an Asthma UK survey, severe asthma significantly hinders 
patient lives, from daily chores to career, relationships, and 
family life [35, 39]. Similar to the checklist item on reliever/
rescue medication use, a previous study in Canada has 
shown that many patients do not follow the recommended 
regimen for their reliever/rescue medications [37]. In this 
Canadian study of 343,520 individuals with asthma con-
tributing to 2.6 million person-years of data, 190,364 (7.3%) 
person-years were categorized as inappropriate reliever users 
and 24,017 (0.9%) as excessive users of reliever medications 
[37]. Consistent with the checklist item on the treatment 
side effects associated with steroid tablets, a previous study 
has demonstrated that patients have reported concerns about 
OCS side effects [35]. Similarly, a questionnaire-based study 
including participants attending an asthma awareness day in 
Norwich, UK, demonstrated that 82% of patients said that 
they disliked taking oral steroids and 12% said that they 
refuse to take them [40]. Weight gain was the most fre-
quent concern, which was reported by 58% of patients [40]. 
Overall, previous studies support the inclusion of concepts 
and items within the PULSAR description and checklist, 
respectively.
The potential for patient-centered prompts to impact on 
clinical practice was recently demonstrated in the UK. Fol-
lowing a national campaign designed to raise awareness of 
persistent cough as a possible sign of lung cancer among 
the general public, urgent PCP referrals for suspected lung 
cancer and lung cancer diagnoses were seen to significantly 
increase compared with the same time in the previous year 
[41]. Furthermore, there was a significant increase in the 
number of surgical resections during the campaign period. 
Therefore, this new patient-centered description of severe 
asthma may improve clinical practice by increasing the num-
ber of appropriate referrals to a respiratory specialist, with 
a more informed patient. Increased referrals of appropriate 
patients will ensure that a greater number of patients with 
severe asthma receive the appropriate level of care, improv-
ing their overall health status (physical and mental) and 
HRQoL. However, although many of the asthma guidelines 
provide guidance on when patients should be referred to a 
specialist [2, 3, 19, 21, 23], these guidelines are not always 
implemented [26]. Many asthma guidelines tend to differ in 
their recommendations, which may lead to confusion among 
HCPs on the most appropriate management strategies in 
severe asthma. In these cases, it is recommended that HCPs 
familiarize themselves with common patient terminology 
and behaviors so that they can refer patients to a specialist, 
when appropriate. GINA has recently provided guidance on 
when to refer patients with severe asthma based on treatment 
response and symptomatic control following the correction/
treatment of several risk factors [3]; however, additional 
HCP training may still be required [42].
Strengths of the PULSAR initiative and description 
include its multidisciplinary approach, robust method-
ology, and patient input. The working group included 
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representatives from different backgrounds, which was 
key to developing a valid and acceptable definition. In 
addition, the PULSAR description underwent a thorough 
review process with these individuals, including a survey 
with patients with severe asthma. Although the PULSAR 
description is limited to English-speaking countries, the 
description will be adapted into the other 45 languages 
of the Global Allergy Asthma Patient Platform (GAAPP) 
member countries with rigorous local language review to 
improve its global application. The PULSAR description 
and checklist will be made available through the GAAPP 
website in the first instance, and then via patient group 
websites. Other possible uses in the future could include 
pamphlets in Emergency Rooms/Accident and Emergency 
departments or through online social media platforms.
There are some potential limitations of the initiative 
that should be discussed. Firstly, the PULSAR descrip-
tion and checklist were developed by a working group 
that included patients with severe asthma, and the subse-
quent survey was conducted in patients with severe asthma 
only. The exclusion of patients without severe asthma may 
have impacted the specificity of the PULSAR descrip-
tion of severe asthma. Secondly, limiting symptoms in 
the description to those that are severe does not rule out 
patients with mild asthma who may have severe symptoms 
during exacerbations. However, as the aim of the PULSAR 
initiative was to increase appropriate referrals by providing 
all patients with asthma with a prompt to go and see their 
doctor about their symptoms, as opposed to developing a 
validated patient-reported outcome for severe asthma, it is 
unlikely that these limitations will detract from the useful-
ness of the description and checklist to patients.
A third potential limitation was the fact that racial/eth-
nic and geographic data were not collected in the survey. 
Studies in patients with asthma have shown that patient 
outcomes are influenced by access to care, and that access 
to care varies according to ethnic/racial background [15]. 
Unfortunately, data on the ethnicity of the survey partici-
pants were not available, limiting our ability to determine 
what different groups of people thought about the PUL-
SAR description and checklist. Another limitation relates 
to the design of the survey questions and the possible 
discordance between a patient’s stated understanding of a 
given concept and the actual meaning of that concept, or 
between one patient’s understanding and that of another. 
For example, if the patient answered ‘Yes’ when asked ‘Do 
you understand what x means?’, their understanding was 
not subsequently checked and confirmed as being correct. 
However, the survey was designed to provide a simple 
‘sense check’ of the PULSAR description and checklist, 
as opposed to a formal validation. Finally, although the 
PULSAR description and checklist were reviewed by an 
individual behavioral scientist, this could have introduced 
a degree of bias and may have benefitted from a wider 
range of views.
7  Conclusion
A novel and patient-centered description has been devel-
oped to improve patient understanding of severe asthma. 
The PULSAR description could help patients assess if they 
have severe asthma, prompting them to visit their PCP, and 
increase the number of appropriate referrals to a specialist.
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